Latest News

 

Beximco Pharmaceuticals Limited (“Beximco Pharma” or “the Company”; AIM Symbol: BXP), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, announces the creation of a joint venture (“JV”) with BioCare Manufacturing (M) Sdn Bhd (“BioCare”) based in Malaysia, as the Company’s first overseas manufacturing collaboration.

Beximco Pharma has received approval for its Metformin Hydrochloride extended-release tablets, 500 mg and 750 mg, from the U.S. Food and Drug Administration (US FDA) on 13th December 2016. These are generic equivalent of Bristol-Myers Squibb′s Glucophage XR tablets, 500 mg and 750 mg.

Sandoz and Beximco Pharmaceuticals Join the Medicines Patent Pool’s Growing Network of Generic Manufacturing Partners

Beximco Pharmaceuticals Limited ("BPL" or "the Company"; AIM Symbol: BXP), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, has received US Food and Drug Administration (FDA) approval for Sotalol Hydrochloride, a generic version of the cardiovascular drug Betapace, following submission of an Abbreviated New Drug Application (ANDA) in June 2014.

First Bangladeshi pharmaceutical company to launch pharmaceutical products in the US

Beximco Pharmaceuticals Limited (“BPL”, “Beximco Pharma” or “Company”; AIM Symbol: BXP), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, today announces it has commenced the export of Carvedilol, a prescription drug for treating hypertension, to the US. This follows the product′s approval from the US Food and Drug Administration (“US FDA”) in November 2015 and is the first time a pharmaceutical product from Bangladesh has been launched in the US.

First time a Bangladeshi pharmaceutical company has launched pharmaceutical products in any gulf member country.

Beximco Pharmaceuticals Limited (“BPL”, “Beximco Pharma” or “Company”), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, announces that it has commenced the export of pharmaceuticals to Kuwait.  This marks the first time a Bangladeshi pharmaceutical company has launched pharmaceutical products in any Gulf member country under the Gulf Cooperation Council (GCC).

Beximco Pharmaceuticals Limited has become the first Bangladeshi pharmaceutical company to receive approval for a prescription drug to be manufactured in this country for export to the USA. The Company says it has been granted formal approval from the U.S. Food and Drug Administration (“U.S. FDA”), following an extensive review of the submitted dossier and its manufacturing processes. This approval allows the Company to manufacture a popular blood pressure drug Carvedilol in different strengths (3.125 mg, 6.25 mg, 12.5 mg, and 25 mg) at the Company′s Tongi facility which recently achieved GMP approval from the US regulatory authority.

Beximco Pharmaceuticals Limited (“BPL”, “Beximco Pharma” or “Company”) becomes the first Bangladeshi pharmaceutical company to be approved by the U.S. Food and Drug Administration (US FDA) following successful inspection of its oral solid dosage facility at Tongi, during January 19-22, 2015. The company says it has received the establishment inspection report (EIR) from the US drug regulatory authority stating that the audit is formally concluded. This is a major milestone for the company as well as for the entire industry as this is the first time a Bangladeshi company has received the prestigious FDA approval. This approval is based on the comprehensive audit encompassing all the systems of drug manufacturing: Quality; Facilities and Equipment; Materials; Production; Packaging and Labeling; and Laboratory Controls. Remarkably, there was no 483 observation issued by the US regulatory authority. A 483 form is issued when FDA has observations of non-compliance or deviation from Good Manufacturing Practices (GMP).

Beximco Pharmaceuticals Limited ("BPL" or "Company"; AIM Symbol: BXP), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, today announces that it has become the first Bangladeshi pharmaceutical company to be audited by the US Food and Drug Administration (“FDA”) without any 483 observation.  A 483 form is issued when the US FDA has observations of non-compliance or deviation from its current Good Manufacturing Practices (“cGMP”).  The inspection of Beximco Pharma’s oral solid dosage manufacturing facility, in Tongi, took place during 19-22 January, 2015.

Country’s leading pharma manufacturer Beximco Pharmaceuticals Ltd makes a foray into Australian Pharma market with the launch of Pantoprazole, a drug for treating gastrointestinal disorder. This is for the first time pharmaceutical product from Bangladesh is being exported to Australia.